Following Lykos Therapeutics’ receipt of a Complete Response Letter (CRL) from the FDA, which is effectively a rejection of its first shot at approval of MDMA-assisted therapy for PTSD, the company has been preparing to navigate the tricky path ahead. While details on the contents of the CRL are slim, we do know the agency has requested an additional Phase 3 study to clarify both the safety and…
